We speak with Innocenzo Genna, independent public affairs consultant advising in telecoms and Internet European regulation. He is also known via his professional blog RadioBruxellesLibera.     How would you evaluate the current increased use of data (especially in non-EU countries) and its effectiveness...

Since the unprecedented outbreak of the COVID-19 virus, the use of data has extensively been discussed. What obstacles do scientists, public health officials and private companies face when processing datasets? And how much digital privacy can EU citizens afford in times of crisis?

We speak with Anna Odone, Associate Professor of Public Health at the Faculty of Medicine of the University Vita-Salute San Raffaele in Milan. As a consultant physician, responsible for the Unit of Clinical Epidemiology and Health Technology Assessment at San Raffaele Scientific Institute, she is the...

Tackling the Covid-19 pandemic, a scientist’s opinion   We speak with Professor Giovanni Rezza, MD, Director of the Department of Infectious Diseases at the Istituto Superiore di Sanità, Roma, Italy about the EU’s announcement of funding for research to tackle Covid-19, and current efforts to develop...

Research efforts to develop treatments against Covid-19   Professor Paul Digard, virologist at The Roslin Institute, University of Edinburgh, tells us about potential routes to Covid-19 treatment and the prospect of having to deal with the virus long-term.     How soon do you think a vaccine against...

Interview with Aroon Hingorani, Professor of Genetic Epidemiology at University College London about Re-engineering pharmaceutical research.     Could you speculate what you think are the biggest causes of drug failure?   Aroon Hingorani: It is well recognised that the number one cause for drug failure...

Interview with Dr Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer (EORTC) about Re-engineering pharmaceutical research.     Can you tell me a bit about the European Organisation for Research and Treatment of Cancer (EORTC)?   Denis Lacombe: We are a non-governmental,...

A so-called ‘productivity crisis’ has been ascribed to the pharmaceutical research and development industry. Despite increases in investment and funding, this has not corresponded to increases in the approval of novel drugs. Why do so many drugs fail to receive approval, and what other means should we...